![]() |
市场调查报告书
商品编码
1610886
积极植入式医疗设备的全球市场:洞察,竞争情形,市场预测:2030年Active Implantable Medical Devices - Market Insights, Competitive Landscape, and Market Forecast - 2030 |
2023年主动式植入式医疗器材市场规模将达250亿美元。预计到 2030 年,该市场将达到 385.7 亿美元,2024 年至 2030 年的预测期间复合年增长率为 7.55%。主动植入式医疗器材市场的推动因素包括神经系统疾病(包括多发性硬化症、癫痫和慢性下背痛)病例的增加、监管部门批准的增加以及市场向微创手术的转变。源植入式医疗器材的偏好日益增加,预计这将在2024-2030年预测期内进一步加速主动式植入式医疗器材市场的整体成长。
根据世界卫生组织 (WHO) 资料(2023 年),据报导全球有超过 180 万人患有多发性硬化症 (MS)。多发性硬化症影响多种功能,包括认知、情绪、运动、感觉和视觉功能。当免疫系统错误地攻击大脑和脊髓时就会发生这种情况。根据世界卫生组织的数据,到2024年,全球将有约5,000万人受到癫痫的影响,使其成为全球最常见的神经系统疾病之一。
在多发性硬化症中,神经刺激器透过调节脊髓和周边神经的神经活动来缓解痉挛和慢性疼痛等症状。对于癫痫症,植入式或响应式神经刺激器可以透过向大脑发送有针对性的电脉衝来帮助减少癫痫发作的频率和严重程度。
2022 年 12 月,雅培实验室宣布美国食品药物管理局 (FDA) 批准 Eterna 脊髓刺激系统,该系统被认为是可用于慢性疼痛治疗的最小的植入式可充电脊髓刺激器。
所有上述因素预计将推动整个主动植入医疗器材市场的成长。
然而,替代设备和疗法的可用性、硬体故障、软体错误、电池消耗等引起的故障可能会对有源植入医疗设备市场的成长带来课题。
本报告提供全球积极植入式医疗设备市场相关调查,提供市场概要,以及各产品类型,各终端用户,各地区趋势,及加入此市场的主要企业简介等资讯。
Active Implantable Medical Devices Market by Product Type (Implantable Cardiovascular Devices [Implantable Cardioverter Defibrillators, Ventricular Assist Devices, Implantable Pacemakers, and Implantable Cardiac Monitors/Insertable Loop Recorders], Implantable Neurostimulators [Deep Brain Stimulators, Spinal Cord Stimulators, Sacral Nerve Stimulators, and Others] Hearing Implants, and Others), End-User (Hospitals, Ambulatory Surgical Centres, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to advance at a respectable CAGR forecast till 2030 owing to the increasing instances of chronic disorders and the rising product developmental activities across the world
The active implantable medical devices market was valued at USD 25 billion in 2023, growing at a CAGR of 7.55% during the forecast period from 2024 to 2030 to reach USD 38.57 billion by 2030. The active implantable medical devices market is observing substantial market growth primarily owing to the increasing instances of chronic disorders like neurological disorders including multiple sclerosis, epilepsy, chronic lower back pain, increasing regulatory approvals, and the rising preference for minimally invasive procedures that are anticipated to further accelerate the overall growth of the active implantable medical devices market during the forecast period from 2024 to 2030.
Active Implantable Medical Devices Market Dynamics:
As per data from the World Health Organization (WHO) (2023), it was reported that over 1.8 million people worldwide are affected by multiple sclerosis (MS). It impacts various functions including cognitive, emotional, motor, sensory, and visual abilities. It occurs when the immune system mistakenly attacks the brain and spinal cord. Data from the WHO stated that in 2024, around 50 million people worldwide had epilepsy, making it one of the most common neurological diseases globally.
In MS, neurostimulators are used to alleviate symptoms such as spasticity and chronic pain by modulating neural activity in the spinal cord or peripheral nerves. For epilepsy, implantable neurostimulators and responsive neurostimulation devices help reduce the frequency and severity of seizures by delivering targeted electrical impulses to the brain.
As per the data from WHO (2023), in 2020, there were 619 million cases of lower back pain and it is projected that the number of lower back pain cases will rise to 843 million by 2050.
Data from the European Pain Federation (2023), stated that 740 million people globally experience an episode of severe pain at some point in their lives on average. For approximately 20% of these individuals, the pain persists for longer than three months, thereby categorizing it as chronic pain. Active implantable medical devices like spinal cord and peripheral nerve stimulators manage chronic and severe pain by delivering targeted electrical stimulation to disrupt pain signals, offering personalized, non-opioid pain relief and improving quality of life.
Additionally, in December 2022, Abbott Laboratories announced the U.S. Food and Drug Administration (FDA) approval for the Eterna spinal cord stimulation system, which was recognized as the smallest implantable, rechargeable spinal cord stimulator that is available for the treatment of chronic pain.
Therefore, all the factors stated above collectively will drive the overall active implantable medical devices market growth.
However, the availability of alternative devices & therapy, malfunction due to hardware failure, software errors, or battery depletion, among others may prove to be challenging factors for the active implantable medical devices market growth.
Active Implantable Medical Devices Market Segment Analysis:
Active Implantable Medical Devices Market by Product Type (Implantable Cardiovascular Devices [Implantable Cardioverter Defibrillators, Ventricular Assist Devices, Implantable Pacemakers, and Implantable Cardiac Monitors/Insertable Loop Recorders], Implantable Neurostimulators [Deep Brain Stimulators, Spinal Cord Stimulators, Sacral Nerve Stimulators, and Others] Hearing Implants, and Others), End-User (Hospitals, Ambulatory Surgical Centres, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)
In the product type segment of the active implantable medical devices market, the implantable neurostimulators category is expected to have a significant revenue share in the year 2023. This can be ascribed to various key features and advantages offered by these devices.
Key features of these devices include precise, programmable stimulation settings that allow for personalized therapy adjustments, rechargeable, and minimally invasive implantation procedures. Advantages include targeted symptom relief, reduced dependency on medications, improved quality of life, and the ability to make real-time adjustments through external controllers. Additionally, many modern neurostimulators offer remote monitoring and adaptive stimulation, which automatically adjusts to the patient's activity level, enhancing treatment efficacy and patient comfort.
Moreover, new product approvals are likely to upsurge the market for the same. For example, in August 2023, Medtronic announced that it received CE Mark approval for the Inceptiv closed-loop rechargeable spinal cord stimulator implant.
Therefore the various features and advantages of implantable neurostimulators solidify the significant impact on the growth of the overall active implantable medical devices market during the forecast period from 2024 to 2030.
North America is expected to dominate the overall active implantable medical devices market:
Among all the regions, North America is expected to dominate the active implantable medical devices market in the year 2023 and is expected to do the same during the forecast period from 2024 to 2030. This can be attributed to several factors, including the increasing prevalence of hearing loss, the growing burden of cardiovascular disorders in the region including myocardial infarction, and ongoing product developmental activities by regulatory bodies that are acting as key factors contributing to the growth of the active implantable medical devices market in the North America region.
As per data from WHO (2024), in 2021, 217 million people were living with hearing loss in the US. The same source further stated that by 2050, 322 million people would be affected by hearing problems in the US. Active implantable medical devices, such as cochlear implants, play a crucial role in managing hearing loss by directly stimulating the auditory nerve and bypassing damaged parts of the ear to restore hearing function.
According to data from the Centers for Disease Control and Prevention (2024), it was stated that 805,000 people in the US have a myocardial infarction (heart attack) every year on average. Also, data from the Canadian Institute for Health Information (2024), stated that in 2022, 2.4 million Canadians were affected by heart disease. Active implantable medical devices are critical in managing heart disease and myocardial infarction by providing real-time monitoring, regulating heart rhythm, and preventing life-threatening cardiac events. In individuals with heart attacks, devices like implantable cardioverter defibrillators and pacemakers help detect abnormal heart rhythms and restore normal function, reducing the risk of sudden cardiac arrest.
Product developmental activities initiated by regulatory bodies will further boost the market for active implantable medical devices. For example, in June 2024, Elutia Inc., a pioneer in drug-eluting biomatrix products, announced that Antibiotic-Eluting BioEnvelope, EluPro (previously known as CanGaroo during development), received clearance from the U.S. Food and Drug Administration (FDA). Designed to prevent post-operative complications for devices like implantable pacemakers and defibrillators, EluPro integrated potent antibiotic therapy with advanced tissue engineering.
Therefore, the interplay of all the aforementioned factors would provide a conducive growth environment for the North American active implantable medical devices market.
Active Implantable Medical Devices Market key players:
Some of the key market players operating in the active implantable medical devices market include Medtronic, Abbott, Jarvik Heart, Inc., Biotronik SE & Co. KG, Boston Scientific Corporation, LivaNova, Inc., Advanced Bionics AG, MicroTransponder Inc., Axonics Modulation Technologies, Inc., Amplifon, MED-EL Medical Electronics., NeuroPace, Inc., NEVRO CORP., MEDICO S.p.A., Aleva Neurotherapeutics S.A., Second Sight, Cochlear Ltd., Sonova, Berlin Heart GmbH, SynCardia Systems LLC, and others.
Recent Developmental Activities in the Active Implantable Medical Devices Market:
Key Takeaways from the Active Implantable Medical Devices Market Report Study
Target Audience who can be benefited from this Active Implantable Medical Devices Market Report Study
Frequently Asked Questions for the Active Implantable Medical Devices Market:
Active implantable medical devices are intended to be totally or partially introduced into the human body for diagnostic or therapeutic purposes and are to remain in place. It includes a wide range of devices, including pacemakers, defibrillators, infusion pumps, ventricular assist systems and devices, cochlear implants, and neurostimulators.
The active implantable medical devices market was valued at USD 25 billion in 2023, growing at a CAGR of 7.55% during the forecast period from 2024 to 2030 to reach USD 38.57 billion by 2030.
The active implantable medical devices market is observing substantial market growth primarily owing to the increasing instances of chronic disorders like neurological disorders including multiple sclerosis, epilepsy, chronic lower back pain, increasing regulatory approvals, and the rising preference for minimally invasive procedures that are anticipated to further accelerate the overall growth of the active implantable medical devices market during the forecast period from 2024 to 2030.
Some of the key market players operating in active implantable medical devices include Medtronic, Abbott, Jarvik Heart, Inc., Biotronik SE & Co. KG, Boston Scientific Corporation, LivaNova, Inc., Advanced Bionics AG, MicroTransponder Inc., Axonics Modulation Technologies, Inc., Amplifon, MED-EL Medical Electronics., NeuroPace, Inc., NEVRO CORP., MEDICO S.p.A., Aleva Neurotherapeutics S.A., Second Sight, Cochlear Ltd., Sonova, Berlin Heart GmbH, SynCardia Systems LLC, and others.
North America is expected to dominate the overall Active Implantable Medical Devices market during the forecast period from 2024 to 2030. This can be attributed to several factors, including the increasing prevalence of hearing loss, the growing burden of cardiovascular disorders in the region including myocardial infarction, and ongoing product developmental activities by regulatory bodies that are acting as key factors contributing to the growth of the active implantable medical devices market in the North America region.